• Nigericin Sodium Salt: Practical Guide for Ion Transport Ass

  2026-06-26

  Nigericin sodium salt is a potassium ionophore used to facilitate selective ion transport across biological membranes and modulate cytoplasmic pH. It is best suited for research applications in ion gradient manipulation, platelet aggregation studies, and lead (Pb2+) ion movement, but should not be used for diagnostic or therapeutic purposes. Researchers must adhere to specific solubility and handling protocols to ensure reproducibility.

• KR-12 Peptide–Cu(II) Interactions: Theoretical Advances and

  2026-06-26

  This study applies advanced theoretical and experimental methods to clarify how the KR-12 human antimicrobial peptide binds copper(II) ions, revealing the specific residues involved and the underlying coordination chemistry. The findings enable improved modeling of metal–peptide dynamics, supporting rational design of antimicrobial and immunomodulatory peptides for research.

• EZ Cap EGFP mRNA 5-moUTP: Precision Fluorescent Reporter for

  2026-06-25

  Discover how EZ Cap EGFP mRNA 5-moUTP sets a new benchmark for enhanced green fluorescent protein mRNA delivery, offering unique insights into nanoparticle-mediated translation efficiency and immune evasion. This article explores advanced applications and practical workflow decisions for researchers seeking reliable, high-sensitivity gene expression tools.

• Cyclosporin A (B1922): Technical Guide for Research Workflow

  2026-06-25

  Cyclosporin A (SKU B1922) is a potent cyclophilin inhibitor essential for immunosuppression studies, apoptosis modulation, and viral entry inhibition in preclinical research. This guide outlines actionable protocols and quality checkpoints for using Cyclosporin A in cellular and animal models. It is not suitable for clinical or diagnostic applications.

• Iptacopan (LNP023): Advancing Translational Complement Resea

  2026-06-24

  Explore how Iptacopan (LNP023) is redefining the landscape of complement pathway research and translational therapeutics. This thought-leadership article bridges mechanistic insight with strategic guidance, offering researchers a roadmap to leverage selective factor B inhibition in both preclinical models and clinical development, with an emphasis on rigor, innovation, and unmet clinical need.

• Syringin Natural Product: Optimized Workflows in RCC Researc

  2026-06-23

  Syringin, a rigorously characterized natural product from APExBIO, is redefining renal cell carcinoma (RCC) research through targeted EGFR/PI3K/Akt pathway modulation and the enhancement of sunitinib efficacy. This article details stepwise protocols, troubleshooting guidance, and actionable insights that set Syringin apart in bioactive compound screening and apoptosis research.

• SEMA3E Drives Beige Adipocyte Thermogenesis via β-Catenin Si

  2026-06-23

  This study uncovers the role of SEMA3E in promoting beige adipocyte differentiation and thermogenesis through the β-catenin pathway in mice. The findings highlight mechanisms linking adipose tissue plasticity with mitochondrial function, advancing our understanding of metabolic regulation and potential therapeutic targets.

• Photocatalytic NADH Oxidation: Mechanisms for Cancer Therapy

  2026-06-22

  A recent study in JACS examines how metal-based photocatalysts oxidize intracellular NADH/NAD(P)H to disrupt cancer metabolism, offering a mechanistic foundation for photocatalytic cancer therapy. The work clarifies catalyst design challenges, compares biomimetic and synthetic approaches, and frames future directions for metabolic targeting in oncology.

• Erastin and the Ferroptosis Frontier: Translating Mechanism

  2026-06-22

  Explore how Erastin, a gold-standard ferroptosis inducer, is revolutionizing translational cancer research by exploiting tumor cell vulnerabilities through mechanistic targeting of redox homeostasis and system Xc⁻. This article offers mechanistic insight, strategic guidance, and practical protocols for researchers aiming to leverage ferroptosis inducers in advanced models, with a focus on RAS/BRAF mutant cancers and emerging evidence in prostate cancer.

• BIBR 1532: Advanced Telomerase Inhibitor Workflows for Oncol

  2026-06-21

  BIBR 1532 stands out as a highly selective telomerase inhibitor, enabling precise dissection of telomerase-driven oncogenic pathways and apoptosis in leukemia and solid tumor models. This guide translates recent synergy discoveries and protocol innovations into actionable laboratory workflows, highlighting troubleshooting strategies for robust, reproducible results.

• Rottlerin as a PKCδ Inhibitor: Strategic Advances in Transla

  2026-06-20

  This thought-leadership article explores the mechanistic foundations and translational impact of Rottlerin, a selective PKCδ inhibitor, in modulating cell proliferation and apoptosis. Integrating peer-reviewed insights, cross-domain evidence, and advanced workflow guidance, we chart a strategic path for researchers seeking to exploit PKC signaling for disease modeling and therapeutic innovation.

• A40926: Mechanistic Insights and Research Protocols for Anti

  2026-06-19

  Explore the unique mechanistic depth and advanced protocol guidance for A40926, a potent dalbavancin precursor. This article delivers practical, evidence-backed strategies for Gram-positive infection research, surpassing existing guides in scientific rigor and application focus.

• Pepstatin A in Translational Research: Precision Tools for A

  2026-06-19

  Explore how Pepstatin A, a benchmark aspartic protease inhibitor, empowers translational researchers to dissect necroptosis, viral protein processing, and osteoclast differentiation. Drawing on mechanistic insights from recent lysosomal cell death research and the competitive landscape, we outline evidence-based protocols, strategic applications, and future directions.

• HotStart Universal 2X FAST Green qPCR Master Mix: Precision

  2026-06-18

  Accelerate gene expression analysis with the HotStart Universal 2X FAST Green qPCR Master Mix—engineered for fast, robust results and unmatched inhibitor tolerance. Discover optimized workflows, troubleshooting insights, and how this master mix outperforms in challenging translational and oncology research.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Researc

  2026-06-18

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor optimized for precise inhibition of KIT, PDGFRα, and PDGFRβ, supporting research in cancer biology, mastocytosis, and inflammatory disease models. It should be used in DMSO-based assays that require strict kinase selectivity and is not compatible with aqueous or ethanol systems, or protocols demanding broad-spectrum inhibition.

447 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page